The Department, with the advice of the Council, shall select the disorders for which screening is required by the Newborn Screening Program. The selected disorders are: Biotinidase deficiency; Congenital adrenal hyperplasia (CAH); Hypothyroidism; Galactosemia, galactose-1-phosphate uridyl transferase deficiency (GALT); Epimerase Galactosemia, uridine diphosphate-galactose-4-epimerase deficiency (GALE); Galactokinase Galactosemia, galactokinase deficiency (GALK1); Sickle cell disease; Sickle cell disease: S beta-thalessemia; Sickle C disease: SC disease; Other hemoglobin variants; Phenylketonuria (PKU); Hyperphenylalaninemia (Hyper-PHE); Biopterin cofactor biosynthesis defects (BIOPT-BS); Biopterin cofactor regeneration defects (BIOPT-REG); Tyrosinemia, type I; Tyrosinemia, type II; Tyrosinemia, type III; Homocystinuria; Hypermethioninemia; Branched chain ketoaciduria (BCK), also called maple syrup urine disease (MSUD); Citrullinemia, type I; Citrullinemia, type II; Arginosuccinic aciduria; Argininemia; Methylmalonic acidemia, mutase deficiency (MMA); Methylmalonic acidemia, adenosylcobalamin synthesis defects A and B (Cbl A, B); Methylmalonic acidemia, adenosylcobalamin synthesis defects C and D (Cbl C, D); Propionic acidemia (PA); Isovaleric acidemia (IVA); Glutaric aciduria type I (GA I); 3-Hydroxy-3-methylglutaryl-CoA (HMG) lysase deficiency; Isobutryl-CoA dehydrogenase (IBCD) deficiency; 2-Methylbutyryl-CoA dehydrogenase deficiency (2MBG); 3-Methlycrotonyl-CoA carboxylase deficiency (3MCC); 3-Methlyglutaconyl-CoA hydratase deficiency (3MGA); 2-Methyl-3-hydroxybutyrl-CoA dehydrogenase deficiency (2M3HBA); Mitochondrial acetoacetyl-CoA thiolase (3-ketothiolase) deficiency (BKT); Multiple carboxylase deficiency (MCD); Malonic acidemia (MAL); Medium chain acyl-CoA dehydrogenase deficiency (MCAD); Medium chain ketoacyl-CoA thiolase deficiency (MCKAT); Short chain acyl-CoA dehydrogenase deficiency (SCAD); Short chain 3-hydroxy acyl Co-A dehydrogenase deficiency (SCHAD); Very long chain acyl-CoA dehydrogenase deficiency (VLCAD) 3-hydroxy long chain acyl-CoA dehydrogenase deficiency (LCHAD); Multiple acyl-CoA dehydrogenase (MAD) or glutaric acidemia type II deficiency (GA II); Carnitine/acylcarnitine translocase deficiency (translocase deficiency); Carnitine palmitoyl transferase type I deficiency (CPT I); Carnitine palmitoyl transferase type II deficiency (CPT II); Carnitine uptake disorder; Trifunctional protein deficiency (TFP); 2,4-dienoyl-CoA reductase deficiency (DE RED); Cystic fibrosis; Severe combined immunodeficiency (SCID); Pompe disease; Fabry disease; Spinal muscular atrophy (SMA); Mucopolysaccharidosis type I (MPS I); Mucopolysaccharidosis Type II (MPS II); X-linked Adrenoleukodystrophy (X-ALD); Guanidinoacetate Methyltransferase Deficiency (GAMT); and Infantile Krabbe Disease. Supplemental Tests. The State’s Newborn Screening Program may not request or perform a supplemental test until the public health laboratory has confirmed there is sufficient blood-spot specimen to test for the required panel of disorders set forth in §B of this regulation.